Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate consisting of the anti-HER2 antibody trastuzumab linked via a non-reducible thioether linker to the maytansinoid anti-tubulin agent DM1. T-DM1 has demonstrated favorable safety and efficacy in patients with HER2-positive metastatic breast cancer. In previous animal studies, T-DM1 exhibited better pharmacokinetics (PK) and slightly more efficacy than several disulfide-linked versions. The efficacy findings are unique, as other disulfidelinked ADCs have shown greater efficacy than thioether linked designs. To explore this further, the in vitro and in vivo activity, PK, and target cell activation of T-DM1 and the disulfide-linked T-SPP-DM1 were examined. Both ADCs demonstrated high in vitro potency, with T-DM1 displaying greater potency in two of four breast cancer cell lines.
-3 -trials for the treatment of cancer (1). One of the most advanced and promising, trastuzumab-emtansine (T-DM1) has shown favorable efficacy and safety in clinical trials for the treatment of patients with HER2-positive metastatic breast cancer (2) (3) (4) . T-DM1 is an ADC that contains the humanized anti-HER2 IgG1 trastuzumab linked to the maytansinoid anti-tubulin agent DM1 via a thioether bond. T-DM1 retains the multiple mechanisms of action (MOA) described for trastuzumab, (5) and conjugation with DM1 confers the potential for additional cell killing activity via the delivery of potent antimitotic maytansinoid catabolites to targeted cancer cells. The efficacy of T-DM1 in patients who progressed on HER2-directed therapies underscores the importance of this additional activity (2) (3) (4) .
T-DM1 is distinct from other clinically tested maytansinoid containing ADCs by virtue of its thioether linker. All other such ADCs in clinical testing utilize disulfidebased linkers (1). The thioether linker is considered more stable because it resists chemical or enzymatic cleavage in biological systems, in contrast to disulfide-based linkers which may be cleaved following thiol-disulfide exchange reactions. T-DM1 was found to be slightly more active in mouse models than T-SPP-DM1 and several other disulfide-linked ADCs (6) . This contrasts with similar studies of other ADCs that led to the selection of disulfide-based linkers for clinical development (7) (8) (9) .
The factors determining the efficacy of an ADC include pharmacokinetics (PK), tumor penetration and accumulation, target binding and cellular uptake, release of active catabolic products, and potency of the catabolic products. Previous studies have shown that the plasma concentrations of thioether-linked ADCs decrease more slowly than those of disulfide-linked ADCs, likely due to greater linker stability (6, 10) ; which may account on June 21, 2017. © 2012 American Association for Cancer Research. mct.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on March 9, 2012; DOI: 10.1158/1535-7163.MCT-11-0727 -4 -for differences in the efficacy between T-DM1 and disulfide-linked analogues. It has also been demonstrated that other aspects of the MOA (i.e., target binding, cellular uptake, and release of catabolic products) may be similar for disulfide-linked and thioether-linked ADCs (11) . To develop a better understanding of the MOA of trastuzumab maytansinoid conjugates and differences in the preclinical activity between these ADCs we investigated the molecular basis for the anti-cancer activity in in vitro and in vivo efficacy, PK, and qualitative and quantitative tumor catabolism studies.
Materials and Methods
All experimental procedures conformed to the principles of the Guide for the Care and Use of Laboratory Animals and the American Physiological Society and were approved by the Institutional Animal Care and Use Committees of the respective laboratories.
Cell lines and reagents
The SK-BR-3 and BT-474 breast carcinoma cell lines were obtained from The American Type Culture Collection and used within 2 months of receipt. The BT-474EEI trastuzumab-resistant breast carcinoma cell line was derived at Genentech (6) N-ethylmaleimide (NEM) and all other chemicals were obtained from Sigma-Aldrich.
The 10 mm C-18 column (0.46 x 25 cm, Vydak) was obtained from the Nest Group. The ULTRA-TURRAX T8 dispersing instrument with an S8N dispersing tool was obtained from IKA Works Inc. Trastuzumab and the humanized anti-glycoprotein D (gD) control antibody, 5B6, were prepared at Genentech. Antibody-[ 3 H]maytansinoid conjugates were prepared at ImmunoGen, Inc., as described previously (12) . The ratio of linked 
Clonogenic assays
Cells were plated at low density (100 cells/well for SK-BR-3, MCF7-neo/HER2 and BT-474EEI; 200 cells/well for BT-474) in Ham's F-12:DMEM (50:50) + 10% FBS + 2 mM L-glutamine and allowed to adhere overnight. Conjugates were added the next day and the cells incubated until colony formation was determined to be maximal. The medium was removed and the colonies stained with crystal violet dye (0.5% in methanol). Colonies were quantified using a GelCount™ (Oxford Optronix). 
In vitro catabolism studies
A stable tritium label was incorporated into the C-20 methoxy group of the DM1 used to prepare the 3 H-labeled conjugates as described previously (12) . HER2dependent processing of the 3 were placed on ice for 2-3 h or for 30 min at 37°C with 6 % CO 2 . The treated cells were then washed three times with fresh medium and incubated at 37°C with 6 % CO 2 with 10 mL fresh culture medium for 3-24 h. The spent medium was separated and cells were harvested at selected time intervals and analyzed for catabolites following acetone extraction as described previously (11, 12) . The precipitates from the acetone extractions were solubilized and analyzed for tritium by liquid scintillation counting (LSC) to assess the level of protein-bound maytansinoid associated with the cell pellet, presumed to be non-metabolized conjugate or DM1 still linked to large protein fragments.
Maytansinoid catabolites were isolated from the medium by solid phase extraction followed by reversed-phase high pressure liquid chromatography (HPLC). Media samples were applied to 6 mL porapak cartridges equilibrated with 3 mL acetone and then with 3 mL water. The cartridges were washed with 4 mL water and the maytansinoids eluted with 4 mL acetone. The eluates were evaporated and analyzed by reversed-phase HPLC and LSC as described for extracts containing the cell catabolites. 
Cell volume measurements
Cell volumes were calculated from average cell diameters as measured using a cell viability analyzer (Beckman Coulter). Cell volumes for the SK-BR-3, BT-474EEI and MCF7/neo-HER2 cells were 3823 μm 3 , 3955 μm 3 , and 3648 μm 3 , respectively.
Animals
Female beige nude XID ® mice (Charles Rivers Laboratory, Hollister, CA) were used for all in vivo studies. Mice were housed in a clean barrier facility in standard rodent micro-isolator cages.
In vivo efficacy studies
To allow comparison of results obtained in vitro and in vivo, a mouse xenograft model was selected that was suitable for both systems. Previously, the founder 5 (Fo5) mouse allograft transplant model was used for in vivo comparisons of maytansinoid ADC efficacy (6) . However, this model was not suitable for these studies as it cannot be cultured in vitro. Thus, the BT-474EEI xenograft model, suitable for in vitro and in vivo investigations, was chosen (13) . BT-474EEI cells (2 x 10 7 ) were injected into the mammary fat pad of beige nude XID mice and tumors were grown to ~250 mm 3 .
Animals were then randomized into nine groups (n=10/group) and treated with a single i.v. bolus dose of 3-18 mg/kg (~60-360 μg/kg based on DM1 dose) of the conjugates.
Tumors were measured with calipers twice weekly for 24 days following dosing, and then weekly for 120 days or until tumors reached a volume of 3000 mm 3 . Tumor volumes were determined using the formula: Tumor volume (mm 3 
In vivo catabolism studies
Mice bearing BT-474EEI tumors (as described above) were randomized into 2 groups (n = 15/group) and treated with a single 300 μg/kg i.v. bolus dose of T- conjugates and sacrificed after 2d. Tumors were homogenized and analyzed for total radioactivity by solubilization and LSC, and maytansinoid catabolites by HPLC and LSC as described previously. To determine the amount of protein-free maytansinoid catabolites present in the tumors, the tumor homogenates were extracted with organic solvent and analyzed as described previously (12) .
Analytical methods
All maytansinoids were separated on an analytical C-18 column equilibrated with 20% aqueous acetonitrile (CH 3 CN) containing 0.025% trifluoroacetic acid (TFA) and using a linear gradient of 2% CH 3 CN min -1 and a flow rate of 1 mL min -1 . The effluent was collected in 6 mL polypropylene scintillation vials (1 mL fractions). Counts per on June 21, 2017. © 2012 American Association for Cancer Research. mct.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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The identities of the catabolites were confirmed by liquid chromatography mass spectrometry (LCMS) by methods similar to those described previously (11) .
Pharmacokinetic studies
Animals (n = 20/group) were administered a 3 mg/kg i.v. bolus dose of T-DM1 or T-SPP-DM1. At selected intervals up to 42 days following dosing, blood samples were collected on a rotational basis, with n = 4 animals per time point. Blood samples were processed for plasma by centrifugation and plasma decanted to polypropylene collection tubes. Samples were stored at -60 to -80ºC until analysis.
ADC plasma concentration analysis
Plasma ADC concentrations were determined with an enzyme-linked immunosorbent assay (ELISA) that measured any trastuzumab antibody containing one or more conjugated DM1 molecules. An anti-DM1 monoclonal antibody was coated on ELISA plates. Captured ADC was detected with biotinylated HER2 extracellular domain (HER2 ECD) followed by streptavidin-horseradish peroxidase. The limit of quantitation (LOQ) was 1.6 ng/mL. Total trastuzumab concentrations were determined as described previously (6) using an ELISA that measured any trastuzumab antibody. In brief, HER2
ECD was coated on ELISA plates. Captured total trastuzumab was detected with goatanti-human IgG-horseradish peroxidase. The LOQ was 1.6 ng/mL. 
Results

HER2-positive breast carcinoma cells display high sensitivity to T-DM1 and T-SPP-DM1
The cytotoxic potencies of T-DM1 and T-SPP-DM1 and the matching nonbinding conjugates were compared in the trastuzumab-sensitive breast cancer cell lines SK-BR-3 and BT-474, and the trastuzumab-insensitive breast cancer cell lines BT-474EEI and MCF7-neo/HER2 using a clonogenic assay ( Fig. 1 ). Both trastuzumab conjugates were found to be potent inhibitors of colony formation in the HER2-positive cell lines, whereas the non-targeting conjugates displayed little cytotoxicity. The chemical nature of the linker had little influence on the cytotoxicity of trastuzumab-DM1 conjugates towards BT-474 ( Fig. 1A) and SK-BR-3 cells ( Fig. 1B) , consistent with an earlier report (6) . However, the T-DM1 was more cytotoxic than T-SPP-DM1 towards BT-474EEI (Fig. 1C ) and MCF7-neo/HER2 cells (Fig. 1D) .
T-DM1 and T-SPP-DM1 display similar efficacy in mice bearing trastuzumabinsensitive BT-474EEI tumors
The anti-tumor activity associated with T-DM1 and T-SPP-DM1 in mice bearing the BT-474EEI tumors is shown in Fig. 2A . Following treatment with trastuzumab conjugates, tumor volume decreased in proportion to dose with maximum response at 18 mg/kg of either conjugate. Tumor regression reached its maximum approximately 10-21 days after dosing with subsequent stasis or re-growth. The exposure-response relationship for T-DM1 and T-SPP-DM1 was similar (Fig. 2B) . The PK of T-DM1 and T-SPP-DM1 are shown in Fig. 3 and Supplementary Table   1 . Total trastuzumab (Tab) PK were similar for both conjugates ( Supplementary Table   1 ), indicating that conjugation with the respective linker-DM1 did not differentially affect the antibody PK behavior. T-SPP-DM1 ADC concentrations decreased more rapidly than T-DM1, with T-SPP-DM1 exhibiting a faster clearance (40.1 ± 1.87 vs. 18.9 ± 0.29 mL/day/kg) and shorter terminal half-life (2.69 ± 0.087 vs. 5.72 ± 0.150 days), consistent with a previous report (6) . Central compartment volume of distribution was similar between the conjugates, as expected, based on the general similarity in their structure.
Pharmacokinetics of T-DM1 and T-SPP-DM1
Characterization of maytansinoid catabolites following in vitro exposure of breast cancer cells to T-DM1 and T-SPP-DM1
The radio-chromatograms in Fig with T-SPP-DM1 and T-DM1, respectively. In separate experiments the total maytansinoids associated with the extract and the precipitate for each time point were equivalent to the amount of conjugate bound at t = 0 (data not shown) indicating that all maytansinoid catabolites had been accounted for (upper curves, Fig. 4B ). Approximately 30% more T-DM1 was bound to cells after the incubation and wash steps than T-SPP-DM1. This, coupled with a higher MAR for T-DM1 compared to T-SPP-DM1 (4.0 vs. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
3.2) accounts for the higher maytansinoid values associated with cells treated with T-
Author Manuscript Published OnlineFirst on March 9, 2012; DOI: 10.1158/1535-7163.MCT-11-0727 -14 -DM1 ( Fig. 4B panels a and b) . The catabolite levels for the conjugates were divided by the total maytansinoids in the sample (acetone pellet + extract ~ conjugate bound at t = 0) to determine the fraction of the conjugates processed to the observed catabolites and replotted in Fig. 4B , panel c. The rates of formation of catabolites from the two conjugates are similar when so normalized. HER2-mediated processing of these conjugates is similar in other breast carcinoma lines (Fig. S1 ).
Catabolism of trastuzumab conjugates within tumor tissue
The concentration of the conjugates in plasma (based on DM1) was calculated from the plasma radioactivity and shown in Fig. 5A . The concentration of T-DM1 after 7 d is about 3-fold greater than the concentration of T-SPP-DM1 (top panel), consistent with the ELISA PK in non-tumor bearing mice (Fig. 3) . The plasma conjugate concentrations (ELISA) in non-tumor-bearing mice (Fig. 3) when adjusted for dose, were approximately 2x higher than the estimated plasma conjugate concentrations derived from the plasma radioactivity measurements in tumor bearing mice, consistent with observations from a separate study (14) . The causes of these discrepancies are not known, but do not affect the interpretation of this study. The plasma concentrations of the nonbinding control conjugates after 2 d were equivalent to the matched trastuzumab conjugates, as expected.
Maytansinoid concentrations in the tumors of mice treated with trastuzumab conjugates were found to reach a maximum level at about 1-2 days with peak concentrations of approximately 700 nmol/L (equivalent to 9% ID/g) or 500 nmol/L, (equivalent to 7% ID/g) for T-DM1 or T-SPP-DM1, respectively, followed by a gradual on June 21, 2017. © 2012 American Association for Cancer Research. mct.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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Based on the HPLC radiochromatograms, the catabolites of the trastuzumab conjugates in tumor tissues were identical to those identified in vitro -lysine-N ε -MCC-DM1 for T-DM1 and lysine-N ε -SPP-DM1 and DM1 for T-SPP-DM1 (Fig. 5B) . The concentrations of the maytansinoid catabolites for the two conjugates ( Fig 5A, bottom panel) were very similar despite the differences in total maytansinoid levels ( Fig. 5A 
Discussion
Interest in ADCs has grown in response to the favorable safety and efficacy associated with T-DM1 and SGN-35 -the latter, an antibody-auristatin conjugate targeting CD30-positive tumors (2, 15) . Additional ADCs are in early clinical trials and more are expected to follow (1, 16) . Efforts to understand the molecular basis for the anti-cancer activities of ADCs have intensified; with studies of maytansinoid and auristatin conjugates providing a mechanistic basis for their clinical activity (11, 12, (17) (18) (19) (20) .
The aims of these studies were to investigate the MOA and anti-cancer activity of T-DM1 and the role of the linker in these processes. To explore the underlying mechanisms determining trastuzumab-maytansinoid ADC activity, in vitro studies were conducted assessing ADC potency and the kinetics of ADC uptake into tumor cells, and the identity and accumulation of the catabolic products. Both trastuzumab conjugates were highly, and similarly, potent against HER2-expressing cell lines (Figure 1 ) (SK-BR-3, BT-474), consistent with a previous report (6) . However, T-DM1 exhibited slightly greater potency in the BT474EEI and MCF7-neo/HER2 cell lines. It is not clear why these cell lines behave differently than the other cell lines tested.
In vitro tumor cell uptake and catabolism studies showed that the uptake and catabolism occurred at a comparable rate for both ADCs (Fig. 4B ). This finding was expected, based on the similarity in HER2 binding affinity of the ADCs (data not shown), indicating that the maytansinoid conjugation does not alter catabolism rate (21) . These studies also showed that lysine-N ε -MCC-DM1 is the sole T-DM1 catabolite accumulating in the tumor cells tested (Fig. 4A) . The high in vitro activation rate for T-DM1 within cancer cells is consistent with its potent cytotoxicity (Fig. 1) and is likely an important factor in its anti-tumor activity.
To explore the in vitro-in vivo correlation of these findings, PK, efficacy, in vivo tumor uptake and catabolism studies were conducted with the HER2+, trastuzumabinsensitive, xenograft tumor BT474EEI. In vivo tumor catabolism data confirmed the in vitro data identifying lysine-N ε -MCC-DM1 as the sole catabolic product ( Figure 5B ).
Previous nonclinical studies reported that T-DM1 displayed slightly greater efficacy than T-SPP-DM1, when compared by dose (6) . It was hypothesized that the greater efficacy of T-DM1, which uses a thioether to link DM1 to the antibody, compared
with T-SPP-DM1, which contains a disulfide linker, may be related to improved PK or differences in the tumor accumulation of active catabolic products. The plasma clearance of T-DM1 is approximately two times slower than T-SPP-DM1 (Supplemental Table 1 ), likely due to greater stability of the thioether linker. This results in greater plasma exposure (AUC) per unit dose of T-DM1, but does not result in a substantive increase in efficacy ( Fig. 2A) . Indeed, comparing ADC efficacy a function of plasma ADC exposure indicates similar in vivo potency (Fig. 2B) .
The greater exposure of T-DM1 compared to T-SPP-DM1 corresponds with increased total tumor maytansinoid concentrations (Fig. 5A) for T-DM1, a logical sequela based on the similarity in the factors determining tumor uptake and binding for both ADCs. However, despite differences in total tumor maytansinoid concentrations, the tumor catabolite exposure levels for the two conjugates are similar ( Figure 5A ). This was not expected, as the higher total maytansinoid concentrations for T-DM1, coupled with the more residualizing nature of its catabolic product predicted higher catabolite concentrations for T-DM1. The reasons for the similarity in tumor catabolite levels are unclear. One possibility is that the primary accumulation of conjugate in the tumor driving the subsequent HER2-mediated catabolism occurs within the first day or so when the plasma concentrations for the two conjugates are similar. Another possibility is that the in vivo cleavage of the disulfide-linked T-SPP-DM1 was more efficient than T-DM1 despite similar in vitro processing rates. and T-SPP-DM1 when both conjugates are administered at the same ADC dose coupled with the slightly greater in vitro potency of T-DM1 in BT474EEI cells would predict greater efficacy for T-DM1; however, no substantive difference in efficacy was observed ( Fig. 2) . This is a unique observation as, in studies with ADCs targeting the CanAg antigen antibody maytansioid conjugate, thioether-linked conjugates were less active than disulfide-linked conjugates, even when tumor catabolite concentrations for the thioetherlinked ADC were somewhat higher than those of the disulfide-linked ADC (12) , an observation attributed to bystander killing (11) (12) (13) . Both the disulfide-linked and thioether-linked anti-CanAg conjugates were efficiently degraded in the lysosomes of 
